Targeting Senescent Cells to Treat Age-Related Chronic Pulmonary Disease
A sizable body of evidence points to a meaningful role for the accumulation of senescent cells in the onset and development of age-related pulmonary conditions such as idiopathic pulmonary fibrosis. These are conditions characterized by chronic inflammation and harmful structural remodeling in lung tissue. Animal studies suggest that senolytic therapies to clear senescent cells can turn back the course of disease. An initial small academic human trial of senolytic treatment in patients with idiopathic pulmonary fibrosis produced promising results, but little to no follow up has occurred. This is the standard problem for generic drugs and otherwise low-cost therapies: since little profit can be made, no-one can raise sufficient capital to pay for the high costs of clinical trials.
Aging is the primary risk factor for most chronic diseases and is accompanied by the progressive accumulation of senescent cells within tissues. While cellular senescence initially serves as a protective mechanism that limits the proliferation of damaged cells, its persistent presence contributes to tissue dysfunction through the secretion of a broad spectrum of inflammatory and profibrotic mediators. The resulting chronic low-grade inflammation, oxidative stress, immune dysregulation, and impaired regenerative capacity are increasingly recognized as hallmarks of age-related pathology. Chronic pulmonary diseases, including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, increase markedly with age and are increasingly regarded as manifestations of accelerated lung aging. Their development and progression are further exacerbated by obesity and type 2 diabetes mellitus, two highly prevalent metabolic disorders characterized by chronic metabolic stress, mitochondrial dysfunction, systemic inflammation, and enhanced accumulation of senescent cells.
Emerging evidence suggests that cellular senescence represents a common biological denominator linking metabolic and pulmonary disease. Through persistent inflammatory and profibrotic signaling, senescent cells establish a self-perpetuating cycle of chronic inflammation, extracellular matrix remodeling, fibrosis, endothelial dysfunction, and impaired tissue repair, thereby driving progressive deterioration of both metabolic and pulmonary function. The recognition of cellular senescence as one of the important drivers of both chronic pulmonary and metabolic diseases has stimulated growing interest in therapeutic strategies aimed at reducing senescent-cell burden or attenuating its detrimental effects. Current approaches include both novel senotherapies specifically targeting cellular senescence, as well as established therapies used in metabolic diseases that have recently been shown to exert senescence-modulating effects. Although clinical evidence remains limited, targeting cellular senescence offers a unique opportunity to address the underlying biology of aging rather than individual disease manifestations.
The medical profession along with the biotech industry has their treatment and research all wrong. Instead of focusing on treating and curing individual diseases like cancer, heart disease, Alzheimer's, arthritis, etc., they need to concentrate on finding ways to slow and stop and eventually reverse aging. And it's not until they view aging itself as a disease that can be treated, will true and significant breakthroughs be achieved. Just think about it. How many 40 year olds have cancer, heart disease, Alzheimer's, arthritis verses 80 year olds. Those as well as a majority of all diseases are directly proportional to aging. If aging was slowed or stopped, those diseases of aging would be reduced or eliminated. While we already have started on a path toward this with drugs like statins and blood pressure meds, we need to step it up a notch to find the actual biological causes of aging and then treatments to address that. That too is being explored with drugs like metformin and rapamycin as well as stem cell therapies, but it's happening at a snail's pace. The government hopes everybody dies off at 65 so they don't have to pay Medicare costs if everybody was living to 120 or 150, so they don't support any studies on aging research. But they ignore the fact that people could be disease-free even at those ages and actually save the government money.